Myriad Genetics, Inc. (MYGN): Price and Financial Metrics


Myriad Genetics, Inc. (MYGN): $18.21

-0.20 (-1.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYGN POWR Grades

  • Value is the dimension where MYGN ranks best; there it ranks ahead of 75.85% of US stocks.
  • The strongest trend for MYGN is in Growth, which has been heading down over the past 177 days.
  • MYGN ranks lowest in Momentum; there it ranks in the 4th percentile.

MYGN Stock Summary

  • MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 125.6 -- higher than 82.5% of US-listed equities with positive expected earnings growth.
  • The ratio of debt to operating expenses for MYRIAD GENETICS INC is higher than it is for about only 18.53% of US stocks.
  • With a year-over-year growth in debt of -49.83%, MYRIAD GENETICS INC's debt growth rate surpasses merely 6.2% of about US stocks.
  • Stocks that are quantitatively similar to MYGN, based on their financial statements, market capitalization, and price volatility, are NUVA, TCX, LPTH, ANGO, and SEMR.
  • MYGN's SEC filings can be seen here. And to visit MYRIAD GENETICS INC's official web site, go to myriad.com.

MYGN Valuation Summary

  • In comparison to the median Healthcare stock, MYGN's EV/EBIT ratio is 518.75% lower, now standing at -33.5.
  • MYGN's price/earnings ratio has moved down 58.6 over the prior 243 months.

Below are key valuation metrics over time for MYGN.

Stock Date P/S P/B P/E EV/EBIT
MYGN 2022-09-23 2.2 1.6 -85.6 -33.5
MYGN 2022-09-22 2.3 1.6 -87.7 -34.3
MYGN 2022-09-21 2.4 1.7 -92.5 -36.2
MYGN 2022-09-20 2.5 1.8 -95.3 -37.3
MYGN 2022-09-19 2.5 1.8 -97.3 -38.0
MYGN 2022-09-16 2.6 1.8 -97.9 -38.3

MYGN Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 36.53%.
  • Its year over year revenue growth rate is now at 20.54%.
  • Its 3 year cash and equivalents growth rate is now at 94.58%.
Over the past 33 months, MYGN's revenue has gone down $162,800,000.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 672.3 -146 -17.6
2022-03-31 682.4 -100.1 -8.2
2021-12-31 690.6 18.2 -27.2
2021-09-30 684.4 13.7 -57.5
2021-06-30 662.3 -6.3 -97.3
2021-03-31 566.1 28.1 -148

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MYGN has a Quality Grade of C, ranking ahead of 61.95% of graded US stocks.
  • MYGN's asset turnover comes in at 0.476 -- ranking 93rd of 681 Pharmaceutical Products stocks.
  • CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.476 0.705 -0.277
2021-03-31 0.404 0.685 -0.395
2020-12-31 0.390 0.680 -0.514
2020-09-30 0.407 0.698 -0.425
2020-06-30 0.424 0.709 -0.380
2020-03-31 0.493 0.737 -0.285

MYGN Price Target

For more insight on analysts targets of MYGN, see our MYGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.25 Average Broker Recommendation 2.11 (Hold)

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $18.21 52-week high $33.18
Prev. close $18.41 52-week low $16.02
Day low $18.02 Volume 497,700
Day high $18.86 Avg. volume 534,955
50-day MA $23.82 Dividend yield N/A
200-day MA $23.40 Market Cap 1.47B

Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study 1 that shows the EndoPredict® breast cancer prognostic test significantly predicted distan

Yahoo | August 31, 2022

Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis

Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.

Yahoo | August 29, 2022

3 Biotech Stocks You Can Buy and Hold for the Next Decade

Investing in biotech stocks can be a leap of faith. Many of those in the sector with the most promising therapies aren't profitable, and some have taken a drubbing so far this year. If you're investing for the long term, however, biotech companies can provide huge potential.

Yahoo | August 29, 2022

Here's Why Investors Should Retain Myriad Genetics (MYGN) Now

Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.

Yahoo | August 26, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted expanded coverage for the use of Myriad’s BRACAnalysis® Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza®(olaparib). “This most recent coverage

Yahoo | August 25, 2022

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo -20.06%
3-mo 0.22%
6-mo -29.64%
1-year -42.45%
3-year -36.04%
5-year -49.67%
YTD -34.02%
2021 39.57%
2020 -27.38%
2019 -6.33%
2018 -15.36%
2017 106.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 19.9682 seconds.